Latest news with #DShanghvi
Economic Times
26-05-2025
- Business
- Economic Times
JM Financial retains Buy on Sun Pharma, lowers target price to Rs 2,025
JM Financial maintains a Buy call on Sun Pharmaceutical Industries, setting a revised target price of Rs 2025. Sun Pharma's Q4FY25 results showed an 8% YoY top-line growth, driven by India formulations and global specialty sales, despite a decline in US formulations. Future growth hinges on Ilumya's Phase 3 data, Leqselvi's launch, and the Checkpoint Therapeutics acquisition. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads (Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of Please consult your financial adviser before taking any position in the stock/s mentioned.) JM Financial has retained a Buy call on Sun Pharmaceutical Industries with a revised target price of Rs 2025 (earlier Rs 2,115). The current market price of Sun Pharmaceutical Industries is Rs 1683.25. The time period given by the analyst is a year when Sun Pharma price can reach the defined target. .Sun Pharmaceuticals Industries, incorporated in 1993, is a Large Cap company with a market cap of Rs 403952.04 Crore) operating in the Pharmaceuticals sector. Sun Pharmaceutical Industries' key products/revenue segments include Pharmaceuticals and Other Operating Revenue for the year ending the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 13571.71 crore, down -4.03 % from last quarter Total Income of Rs 14141.08 crore and up 7.81% from last year same quarter Total Income of Rs 12,588.84 crore. The company has reported net profit after tax of Rs 2160.64 crore in latest company's top management includes S Shanghvi, D Shanghvi, V Valia, Goenka, Bijapurkar, Doshi, Asher, Hoffmann. Company has S R B C & Co. LLP as its auditors. As on 31-03-2025, the company has a total of 240 crore shares outstanding. Sun Pharma delivered a moderate Q4FY25, with results broadly in line with expectations. The company reported a top-line growth of 8% YoY in Q4FY25, with EBITDA and adjusted PAT growth of 22% and -11% YoY, respectively. Revenue, EBITDA, and adjusted PAT were down 1%, up 4%, and down 13% vs. JMFe. India formulations grew 13.6% YoY, maintaining its number-one rank with an 8.3% market share. Global specialty sales rose 8.6% YoY, driven by a 17% increase in Ilumya sales, while emerging markets (EM) grew 11.5% YoY in constant currency (CC), led by Romania, Russia, and Brazil. However, US formulations declined 2.5% YoY in CC due to weakness in the generic segment, despite growth in specialty brands like Ilumya and company launched 10 products each in India and the US in Q4FY25, strengthening its portfolio. Future growth is anchored in the Phase 3 data release of Ilumya in 2H CY25, the delayed launch of Leqselvi in 2QFY26, and the acquisition of Checkpoint Therapeutics, which enhances its oncology portfolio. With a focus on compliance for US plants, new product trials, and strategic Mundefined10% growth over FY25?28 on a large base. JM Financial maintains a positive outlook on the stock and reaffirms its BUY recommendation with a target price of Rs 2,025 (earlier Rs 2,115.)Promoters held 54.48 per cent stake in the company as of 31-Mar-2025, while FIIs owned 17.95 per cent, DIIs 18.48 per cent.
Time of India
26-05-2025
- Business
- Time of India
JM Financial retains Buy on Sun Pharma, lowers target price to Rs 2,025
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel JM Financial has retained a Buy call on Sun Pharmaceutical Industries with a revised target price of Rs 2025 (earlier Rs 2,115). The current market price of Sun Pharmaceutical Industries is Rs 1683.25. The time period given by the analyst is a year when Sun Pharma price can reach the defined target. .Sun Pharmaceuticals Industries, incorporated in 1993, is a Large Cap company with a market cap of Rs 403952.04 Crore) operating in the Pharmaceuticals sector. Sun Pharmaceutical Industries' key products/revenue segments include Pharmaceuticals and Other Operating Revenue for the year ending the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 13571.71 crore, down -4.03 % from last quarter Total Income of Rs 14141.08 crore and up 7.81% from last year same quarter Total Income of Rs 12,588.84 crore. The company has reported net profit after tax of Rs 2160.64 crore in latest company's top management includes S Shanghvi, D Shanghvi, V Valia, Goenka, Bijapurkar, Doshi, Asher, Hoffmann. Company has S R B C & Co. LLP as its auditors. As on 31-03-2025, the company has a total of 240 crore shares Pharma delivered a moderate Q4FY25, with results broadly in line with expectations. The company reported a top-line growth of 8% YoY in Q4FY25, with EBITDA and adjusted PAT growth of 22% and -11% YoY, respectively. Revenue, EBITDA, and adjusted PAT were down 1%, up 4%, and down 13% vs. JMFe. India formulations grew 13.6% YoY, maintaining its number-one rank with an 8.3% market share. Global specialty sales rose 8.6% YoY, driven by a 17% increase in Ilumya sales, while emerging markets (EM) grew 11.5% YoY in constant currency (CC), led by Romania, Russia, and Brazil. However, US formulations declined 2.5% YoY in CC due to weakness in the generic segment, despite growth in specialty brands like Ilumya and company launched 10 products each in India and the US in Q4FY25, strengthening its portfolio. Future growth is anchored in the Phase 3 data release of Ilumya in 2H CY25, the delayed launch of Leqselvi in 2QFY26, and the acquisition of Checkpoint Therapeutics, which enhances its oncology portfolio. With a focus on compliance for US plants, new product trials, and strategic M&A, the company is poised for >10% growth over FY25?28 on a large base. JM Financial maintains a positive outlook on the stock and reaffirms its BUY recommendation with a target price of Rs 2,025 (earlier Rs 2,115.)Promoters held 54.48 per cent stake in the company as of 31-Mar-2025, while FIIs owned 17.95 per cent, DIIs 18.48 per cent.
